Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.
Nineteen transfusion-dependent beta-thalassemia major patients were included in the study. Six of these patients underwent chelation therapy with desferrioxamine by subcutaneous infusion (50 mg/kg/12 hr) and 13 received intravenous infusion (50 mg/kg/6 hr or 100 mg/kg/24 hr). BUN, creatinine, creatinine clearance, beta 2-microglobulin, urinary beta 2-microglobulin and urinary growth hormone excretion were evaluated during desferrioxamine treatment. Thirteen out of nineteen patients presented tubular damage indicated by increased excretion of urinary beta 2-microglobulin. 85% (11 of 13) of these patients showed more serious tubular damage, as demonstrated by concurrent increased urinary growth hormone excretion. Moreover, a positive correlation between urinary growth hormone excretion and urinary beta 2-microglobulin was observed (P < 0.05).
Cianciulli
P
P
Centro Microcitemie, Ospedale S. Eugenio, Università Tor Vergata, Rome, Italy.
Sollecito
D
D
Sorrentino
F
F
Forte
L
L
Gilardi
E
E
Massa
A
A
Papa
G
G
Carta
S
S
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D013006:Growth Hormone / Q000652:urine; D006801:Humans; D015592:Immunoradiometric Assay; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D007677:Kidney Function Tests; D008297:Male; D001613:beta 2-Microglobulin / Q000652:urine; D017086:beta-Thalassemia / Q000628:therapy* / Q000652:urine
D001613:beta 2-Microglobulin; D013006:Growth Hormone; D003676:Deferoxamine